Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Conditions
Interventions
OTX-TKI (axitinib implant)
Aflibercept
Locations
108
United States
Associated Retina Consultants - Gilbert
Gilbert, Arizona, United States
Associated Retina Consultants - Phoenix
Phoenix, Arizona, United States
Retinal Research Institute
Phoenix, Arizona, United States
Retina Macula Institute of Arizona
Scottsdale, Arizona, United States
CA CRC California Retina Consultants
Bakersfield, California, United States
The Retina Partners - Encino
Encino, California, United States
Start Date
January 29, 2024
Primary Completion Date
April 29, 2026
Completion Date
September 27, 2027
Last Updated
April 18, 2025
NCT07308639
NCT06439576
NCT05562947
NCT05904028
NCT06213038
NCT06492863
Lead Sponsor
Ocular Therapeutix, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions